100 KING STREET WEST, TORONTO, A6
Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Appoints Dr. Suresh Durgam to Board of Directors
Reports Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 for October 2026
Reports Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934
Changes Name from Cybin Inc. to Helus Pharma Inc.
Announces Completion of Legal Name Change
To Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Annual Report of Foreign Private Issuer Pursuant to Section 13(a) or 15(d)
Amended Annual Report of Foreign Private Issuer Pursuant to Section 13(a) or 15(d)
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Supplemental Filing
Free Writing Prospectus
Appointment of Agent for Service of Process by Foreign Banks and Foreign Insurance Companies
Registration Statement for Securities of Certain Canadian Issuers